OTC · ACORQ
Acorda Therapeutics, Inc.
$0.01-$0.00 (-24.81%)
Acorda Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.94% below the high.
Loading market information…
OTC · NAVBQ · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Navidea Biopharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.77% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Navidea Biopharmaceuticals, Inc.’s next earnings report is currently expected on Nov 16, 2026, with estimated earnings per share of -$0.08. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Navidea Biopharmaceuticals, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical firm dedicated to advancing and commercializing specialized agents for immunodiagnosis and innovative immunotherapeutics. The company operates across two distinct segments: Diagnostic Substances and Therapeutic Development Programs. Its core technology, the Manocept platform, is designed to target the CD206 mannose receptor, which is prominently found on activated macrophages. This platform enables a variety of diagnostic imaging techniques, including single photon emission computed tomography (SPECT), positron emission tomography (PET), gamma-scanning, and both intra-operative and optical-fluorescence detection methods. Beyond diagnostics, Manocept also facilitates the targeted delivery of therapeutic compounds to macrophages, addressing diseases characterized by immune system involvement and inflammation. Among its key pipeline assets, NAV3-31 has successfully completed Phase IIb clinical trials. These trials assessed the imaging repeatability, reproducibility, and stability, along with the effectiveness of Tc99m tilmanocept imaging in monitoring anti-tumor necrosis factor alpha therapy for patients with moderate to severe rheumatoid arthritis (RA). NAV3-35 is currently undergoing a Phase IIb clinical trial for RA imaging, while NAV3-33 is advancing through Phase III clinical trials, also for RA. Furthermore, NAV3-32 is participating in a Phase 2b trial specifically for RA-involved joints. The company is also exploring the utility of Tc99m tilmanocept in other therapeutic areas, such as cardiovascular conditions, Kaposi's sarcoma, tuberculosis, and various other immunotherapeutic applications. Originally established as Neoprobe Corporation, the company officially adopted the name Navidea Biopharmaceuticals, Inc. in January 2012. Founded in 1983, its corporate headquarters are situated in Dublin, Ohio. In a significant corporate development, Navidea Biopharmaceuticals, Inc. initiated voluntary reorganization proceedings under Chapter 11 with the U.S. Bankruptcy Court for the District of Delaware on October 1, 2025.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:21 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $51.01K+2.01% vs estimate |
| Q4 2021 | Mar 23, 2022 | -$0.12-300.0% vs estimate | $50.35K-97.2% vs estimate |
|---|
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
THE ANALYST VIEW
8 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.01-$0.00 (-24.81%)
Acorda Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.94% below the high.
$0.00$0.00 (0.0%)
MagForce AG: Healthcare · Medical - Devices.
$0.00$0.00 (0.0%)
Nanomix Corporation’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.01$0.00 (0.0%)
NeonMind Biosciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.67% below the high.
$0.00-$0.00 (0.0%)
MobileSmith, Inc.: Healthcare · Medical - Healthcare Information Services.
$0.00$0.00 (0.0%)
Gelesis Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.0% below the high.
$0.00+$0.00 (+9,900.0%)
Gene Biotherapeutics, Inc.: Healthcare · Biotechnology.
$0.00$0.00 (0.0%)
Goodbody Health Limited’s quoted price sits in the lower half of its reported 52-week range, 90.0% below the high.
